ZYDUS WELLNESS LTD.-$ - 531335 - Board Meeting Outcome for Outcome Of The Board Meeting
Outcome of the Board Meeting held on May 17, 202217-05-2022
17-05-2022
ZYDUS WELLNESS LTD.-$ - 531335 - Audited Financial Results For The Quarter/Year Ended On March 31, 2022
Outcome of the Board meeting for Audited Financial Results for the quarter/year ended on March 31, 202217-05-2022
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol
Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statins13-05-2022
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company has scheduled investor interaction through a teleconference call at 5:30 p.m. (IST) on Tuesday, May 17, 2022, post announcement of audited financial results for the quarter / year ended on March 31, 202213-05-2022
ZYDUS WELLNESS LTD.-$ - 531335 - Board Meeting Intimation for Approval Of The Audited Financial Results For The Quarter / Year Ended On March 31, 2022 And To Recommend Final Dividend For The Financial Year Ended On March 31, 2022
ZYDUS WELLNESS LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2022 ,inter alia, to consider and approve To consider apart from other agenda items to approve the audited financial results for the quarter / year ended on March 31, 2022 and to recommend final dividend for the financial year ended on March 31, 202210-05-2022
Zydus Lifesciences gets USFDA's nod to market generic version of Bortezomib
The approval by the US Food and Drug Administration (USFDA) is for single-dose vial of Bortezomib for injection of strength 3.5 mg/vial, the company said in a regulatory filing.03-05-2022
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement published in the Financial Express English and Gujarati Edition with regard to the Notice to the shareholders for claiming their shares which are liable to be transferred to Investor Education and Protection Fund (''IEPF'').03-05-2022
DCGI okays emergency use of Zydus' two-jab Covid-19 vaccine for 12 yrs-plus
With this, vaccine will now be administered on day 0 and day 28. Earlier, it was approved as a triple dose on day 0, day 28 and day 5626-04-2022
ZYDUS WELLNESS LTD.-$ - 531335 - Zydus Wellness Ltd reply to clarification sought by the exchange
The Exchange has sought clarification from Zydus Wellness Ltd with respect to news article appearing on https://www.business-standard.com dated April 15, 2022 (Link: https://www.business-standard.com/article/companies/sec-approves-two-dose-regimen-of-zydus-covid-19-vaccine-zycov-d-122041500020_1.html) titled "SEC approves two-dose regimen of Zydus Covid-19 vaccine ZyCoV-D".Zydus Wellness Ltd response is enclosed.19-04-2022